Among the options to successfully lower atherogenic blood lipids are therapeutics against drug targets that when mutated cause familial hypercholesterolemia (FH), such as NPC1L1, the target of ezetimibe, or PCSK99. Here, NPC1L1 is linked to familial hyperaldosteronism.